Sainex Met Chem Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
as on 23-12-2024
- Paid Up Capital ₹ 1.25 Cr
as on 23-12-2024
- Company Age 6 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.62 Cr
as on 23-12-2024
- Revenue 858.62%
(FY 2022)
- Profit -200.43%
(FY 2022)
- Ebitda -225.47%
(FY 2022)
- Net Worth -4.50%
(FY 2022)
- Total Assets 49.58%
(FY 2022)
About Sainex Met Chem Pharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 1.25 Cr.
The company currently has active open charges totaling ₹2.62 Cr.
Vinod Patel, Mahendrakumar Dharsandia, Jayeshkumar Dadhania, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24304GJ2018PTC102544
- Company No.
102544
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 May 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Valsad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sainex Met Chem Pharma?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod Patel  | Director | 25-May-2018 | Current |
| Mahendrakumar Dharsandia | Director | 25-May-2018 | Current |
| Jayeshkumar Dadhania | Director | 01-Jun-2018 | Current |
| Hareshkumar Makadia | Director | 01-Jun-2018 | Current |
| Chintan Shah | Director | 23-Nov-2023 | Current |
| Rajeshkumar Depani | Director | 01-Apr-2021 | Current |
Financial Performance of Sainex Met Chem Pharma.
Sainex Met Chem Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 858.62% increase. The company also saw a substantial fall in profitability, with a 200.43% decrease in profit. The company's net worth dipped by a decrease of 4.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sainex Met Chem Pharma?
In 2020, Sainex Met Chem Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Oct 2019 | ₹2.62 Cr | Open |
How Many Employees Work at Sainex Met Chem Pharma?
Unlock and access historical data on people associated with Sainex Met Chem Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sainex Met Chem Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sainex Met Chem Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
